 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Telesis Bio appoints William Kullback as CFO

SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial...

Telesis Bio Appoints William J. Kullback Chief Financial Officer

KeyBanc Capital Marketsanalyst Paul Knight downgradedTelesis Bio, Inc.(NASDAQ: TBIO) to

Latest Ratings for TBIO

DateFirmActionFromTo Aug 2021Roth CapitalMaintainsNeutral Aug 2021SVB LeerinkMaintainsMarket Perform Aug 2021William BlairDowngradesOutperformMarket Perform

 View More Analyst Ratings ...

Pfizer Collaboration Offers Potential Milestone Windfalls For TBIO, Despite Financial Hurdles: Analyst

-- Total revenue of $8.7M in 2QFY23 - increased by 53% year over yearSAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. We achieved important ...

Telesis Bio Reports Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio(Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the ...

Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023,...

Telesis Bio to Present at Jefferies Healthcare Conference 2023

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discoverySAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their automated ...

Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in...

Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock

Telesis Bio gets $28 million in financing through preferred stock private placement

Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology ...

Telesis Bio Secures Financing of $28.0 Million

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Watchers	2,910
52-Wk Low	$1.05
52-Wk High	$3.32

Market Cap	$35.94M
Volume (M)	4,163.00
52-Wk High	$3.32
52-Wk Low	$1.05

TBIO Translate Bio, Inc.

About

Feed

News

Earnings

Fundamentals